North America Defibrillators Market

North America Defibrillators Market Size (2023 to 2028)

The size of the defibrillators market in North America was approximately USD 4.73 billion in 2023 and is projected to grow at a CAGR of 7.3% to reach USD 6.73 billion by 2028.

The growing elderly population primarily drives the market for defibrillators in North America, an increase in the prevalence of cardiac disorders, increase in the rapid innovations and technical developments with life-saving devices.

People opting for early defibrillation as the sooner someone is defibrillated after a cardiac arrest, the higher the chances of survival. It is basically due to the flow of oxygenated blood around the body, which decreases and finally ceases if the heart stops pumping efficiently. When vital organs are deprived of oxygen-rich blood, they begin to die.

Increase the survival rates by 50-70 percent if the defibrillator is used within 3-5 minutes of collapsing of the patient. Also, an increase in the awareness of the importance of good cardiac health and market players are estimated to further drive the defibrillators market growth in North America.

Due to an increase in risk factors like skin burns, myocardial necrosis, side effects, fear of implantation, spreading of infection with rising in the cost of the medical devices. Also, a rise in the number of product failures, lack of awareness in some areas is estimated to hamper the market growth of the defibrillators.

Impact of COVID-19 on the North American defibrillators market:

COVID-19 has hit lots of sectors and created a huge impact on supply and demand rates. With increasing in cost and demand rates. Due to the delay of cardiovascular operations classified as elective surgeries, the market for defibrillators suffered a negative growth rate of 7.20 percent from 2019 to 2020. In 2022, the market is anticipated to expand at an annual rate of 8.15 percent. COVID-19 pandemic has changed many elements in the healthcare sector, including the treatment for cardiac arrest; therefore, concentrating on the defibrillation techniques can help reduce delayed treatments of the patients.

This research report on the North American defibrillators market has been segmented and sub-segmented into the following categories.

By Product:

• Implantable Defibrillators
  • Transvenous Implantable Cardioverter Defibrillator (T-ICDs)
  • Subcutaneous Implantable Cardioverter Defibrillator (S-ICDs)
  • Cardiac Resynchronization Therapy- Defibrillator (CRT-D)
• External defibrillators
  • Manual External Defibrillator
  • Automated External Defibrillator (AEDs)
  • Wearable Cardioverter Defibrillator (WCDs)

By End User:

• Hospitals
• Prehospital
• Public Access market
• Alternate Care Market
• Home

By Country:

• The United States
• Canada
• Rest of North America

Regionally, North America was leading the global defibrillator market in 2022. Defibrillators are of different types: manual external defibrillator, manual internal defibrillator, automated external defibrillator (AED), implanted cardioverter-defibrillator (ICD), and wearable cardiac defibrillator are all examples of these devices accounting for 35.0 percent of sales. This is due to the presence of numerous firms in the US. There are presently about 3.2 million AEDs in public locations. Still, more than 30 million AEDs are needed to ensure adequate coverage and increase the national SCA survival rate, which is currently less than 8%.

Each year up to 45,000 Canadians experiences sudden cardiac arrest, according to the Heart and Stroke Foundation of Canada. It's critical to get cardiopulmonary resuscitation (CPR) and defibrillation as soon as possible following a cardiac arrest (1 to 3 minutes;) therefore, automated external defibrillators are used as they are small and portable and have 75 percent of surviving chances.

KEY MARKET PLAYERS:

A few of the prominent companies leading the North America defibrillators market profiled in the report are Medtronic PLC (Ireland), St. Jude Medical, Inc. (U.S.), Boston Scientific Corporation (U.S.), BIOTRONIK SE & Co. KG (Germany), LivaNova PLC (U.K.), Koninklijke Philips N.V. (Netherlands), ZOLL Medical Corporation (U.S.), Cardiac Science Corporation (U.S.), Physio-Control, Inc. (U.S.), and Nihon Kohden Corporation (Japan).